NASDAQ
24.04.26 | 22:00
0,676 US-Dollar
+10,77 % +0,066
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 27.03. | Citizens cuts Tela Bio stock price target on commercial transition | 2 | Investing.com | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 25.03. | TELA Bio Analysts Cut Their Forecasts After Q4 Results | 1 | Benzinga.com | ||
| 25.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.03. | TELA Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | Piper Sandler cuts TELA Bio stock price target on lowered outlook | 1 | Investing.com | ||
| 25.03. | Piper Sandler senkt Kursziel für TELA Bio nach schwächerem Ausblick | 1 | Investing.com Deutsch | ||
| 25.03. | Jefferies senkt Kursziel für TELA Bio wegen schwächerer Wachstumsaussichten | 2 | Investing.com Deutsch | ||
| 25.03. | Jefferies cuts TELA Bio stock price target on slower growth outlook | 2 | Investing.com | ||
| 25.03. | Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation | 1 | Seeking Alpha | ||
| 24.03. | TELA Bio: Gewinn übertrifft Erwartungen, doch Umsatz enttäuscht - Aktie bricht ein | - | Investing.com Deutsch | ||
| 24.03. | TELA Bio GAAP EPS of -$0.17 beats by $0.01, revenue of $20.9M misses by $0.14M | 2 | Seeking Alpha | ||
| 24.03. | TELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results | 398 | GlobeNewswire (Europe) | MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 20.03. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | TELA Bio, Inc.: TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 20.02. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 23.01. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 23.12.25 | BD faces hernia mesh lawsuit from Tela Bio | 7 | MassDevice | ||
| 23.12.25 | Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly | 4 | Benzinga.com | ||
| 12.12.25 | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 43,480 | +0,49 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -0,23 % | Mesoblast: Neue Fantasie durch Technologie - und ein wachsender Zielmarkt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,331 | -0,37 % | PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing | MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics... ► Artikel lesen | |
| MYRIAD GENETICS | 4,196 | +2,97 % | Myriad Genetics, Inc.: Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan | SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,200 | -2,44 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,380 | +0,19 % | Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth | ||
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm plc - 15-12G, Securities registration termination | ||
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential |
TELA BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +10,77 % bei einem Aktienkurs von 0,676 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.